Back to Blog
Beginner's GuidePeptide Science

How Do Peptides Work? A Beginner's Guide

Peptides are everywhere in 2026 — from NEJM trial results to TikTok feeds. This guide breaks down peptide science from first principles: receptor binding, signal transduction, compound types, stability, and the current research landscape.

PeptideTB500 Editorial Last updated: April 24, 2026 16 min read
Educational overview — for laboratory research use only. This page describes the general biochemistry of peptides and summarizes major categories. Several peptides discussed (semaglutide, tirzepatide) are FDA-approved prescription medications used under medical supervision in their approved indications. Most others (BPC-157, TB-500/Tβ4, CJC-1295, Ipamorelin, IGF-1 LR3, GHK-Cu, Epithalon, SNAP-8) are research chemicals not approved for any human therapeutic indication. Nothing on this page is medical advice or a recommendation to self-administer.

What Are Peptides?

At the molecular level, peptides are chains of amino acids linked by peptide bonds — covalent amide linkages formed through a dehydration synthesis reaction. The defining characteristic is their length: peptides consist of approximately 2 to 50 amino acids. Anything longer is generally classified as a protein.

Their smaller size gives them distinct pharmacological advantages over proteins and traditional small-molecule drugs: faster absorption, greater tissue penetration, and higher target specificity. Your body already produces thousands of naturally occurring peptides — insulin (51 aa), oxytocin (9 aa), GLP-1 (30 aa), and GHK (3 aa) — which serve as the biological templates from which synthetic research peptides are derived.

FeaturePeptidesProteins
Amino acid count2–5050–30,000+
Molecular weight< ~5,500 Da> ~5,500 Da
Structural complexityLinear or simple cyclicComplex tertiary/quaternary folds
SynthesisSolid-phase (SPPS)Recombinant expression
StabilityRequires lyophilizationMore stable in solution

How Peptides Work in the Body

1. Receptor Binding

Peptides act as ligands — molecules that bind specific receptors, typically on cell surfaces. Binding specificity is determined by molecular complementarity (shape, charge, hydrophobicity). Semaglutide, for example, binds GLP-1R, a G protein–coupled receptor, with downstream effects on appetite signaling and insulin secretion documented in the STEP semaglutide trials [3].

2. Signal Transduction

Receptor activation translates into intracellular responses. Major peptide-relevant pathways include cAMP/PKA (GLP-1 agonists), PI3K/Akt/mTOR (IGF-1 family — extensively studied as the dominant axis for muscle protein synthesis in animal work), and MAPK/ERK signaling. The signaling step is where peptide categories diverge mechanistically.

3. Biological Effect

Downstream effects depend on the receptor system engaged. Semaglutide produces glucose-lowering and weight reduction in human trials [3]; BPC-157 produces vascular and tissue-repair effects in rodent injury models [8]; Tβ4 (TB-500) produces effects on cell migration and cardiac repair in animal models [9]. The effect set varies widely by compound — "peptides" is a structural class, not a functional one.

Major Peptide Categories

A non-exhaustive map. Trial outcome figures are from the cited published trials — they describe results in those study populations, not predictions for any individual reader.

GLP-1 Receptor Agonists — Metabolic / Weight
Strongest human evidence base in this list — large peer-reviewed Phase 3 RCTs.
SemaglutideGLP-1 RA · FDA-approved (Wegovy / Ozempic) · STEP 1 mean weight change −14.9% vs −2.4% placebo at 68 weeks [3]
TirzepatideDual GIP/GLP-1 RA · FDA-approved (Zepbound / Mounjaro) · SURMOUNT-1 mean weight reduction up to −22.5% at 72 weeks (15 mg) [4]
RetatrutideTriple GIP/GLP-1/glucagon RA · investigational · Phase 2 NEJM mean weight loss −24.2% at 48 weeks (12 mg) [5]
Growth Hormone Secretagogues
Limited human PK/endocrine data; muscle-mass efficacy in healthy people not established.
CJC-1295Modified GHRH analog · Teichman 2006 reported dose-dependent GH/IGF-1 elevation in healthy adults, half-life ≈5.8–8.1 days [1]
IpamorelinSelective GHS-R1a agonist · Raun 1998 characterized GH release without significant ACTH/cortisol effects in animal models [2]
MK-677 (Ibutamoren)Small-molecule oral ghrelin mimetic — not a peptide; included because it engages the same receptor as ipamorelin
Tissue Repair Peptides (Animal-Model Evidence)
Predominantly preclinical (rodent, in vitro). Human controlled trials for tissue repair are essentially absent.
BPC-15715-aa pentadecapeptide derived from a gastric protective protein. Rodent studies report tendon healing and angiogenic effects [8]; most data come from a single research group — independent reviews flag this as a limitation
TB-500 / Tβ4TB-500 = synthetic active fragment of Thymosin Beta-4. Animal studies report cell-migration, cardiac and dermal repair effects [9]; human PK data limited
IGF-1 LR3Modified IGF-1 with reduced IGFBP affinity, designed for greater bioactivity per dose in animal studies. Specific human half-life claims circulating online are not well-supported in peer-reviewed literature
Cosmetic and "Longevity" Peptides
Mostly in vitro and animal data, plus manufacturer/product literature. Specific percentage claims often originate from small or sponsor-funded studies — interpret cautiously.
GHK-CuCopper-binding tripeptide studied for skin and wound effects in vitro and animal models. Broad gene-expression effects reported in cell-culture work; specific human cosmetic outcome percentages vary by study
Epithalon (AEDG)Synthetic tetrapeptide studied by the Khavinson group for telomere/longevity endpoints. Long-term human evidence is limited; many cited mortality findings come from non-Western journals not widely independently replicated
SNAP-8 (Acetyl Octapeptide-3)Cosmetic peptide marketed for expression-line softening; specific wrinkle-depth percentages typically come from manufacturer/cosmetic-industry studies rather than independent clinical trials
START RESEARCHING

Pre-Built Stacks from our supplier

Budget, Clavicular, and Ultimate stacks — curated combinations with research-grade peptides at every price point.

View All Stacks

Peptide Stability & Storage

Why Lyophilization Matters

In aqueous solution, peptides undergo hydrolysis, oxidation, and aggregation. Lyophilization (freeze-drying) removes water, dramatically slowing these degradation pathways. Properly stored lyophilized peptides maintain stability for 24–36 months at -20°C.

StateTempDuration
Lyophilized (frozen)-20°C2–3 years
Lyophilized (fridge)2–8°C1–2 years
Reconstituted2–8°C2–6 weeks
General Reconstitution Notes
  • Multi-use vials are typically reconstituted with bacteriostatic water (preserved with 0.9% benzyl alcohol) rather than sterile water
  • Researchers commonly direct the diluent stream down the inner vial wall, not directly onto the lyophilized powder
  • Vigorous shaking can promote peptide degradation through air-liquid interface effects — gentle swirling is preferred
  • Reconstituted peptides are kept refrigerated, not frozen — freezing can damage peptide structure via ice crystal formation
  • Always follow the supplier's product-specific reconstitution and storage guidance

These are general handling notes from the peptide research literature, not dosing instructions.

Common Misconceptions

"Peptides are steroids."

Structurally distinct. Anabolic-androgenic steroids are lipid-derived molecules built around a four-ring carbon (sterane) nucleus. Peptides are short amino-acid chains. Different chemistry, different receptors, different downstream effects.

"All peptides are illegal."

Legal status varies by compound and jurisdiction. Semaglutide and tirzepatide are FDA-approved prescription medications. Retatrutide is investigational. Most other peptides discussed (BPC-157, TB-500, CJC-1295, Ipamorelin, IGF-1 LR3, GHK-Cu, Epithalon) are sold as research chemicals — laws governing their sale, possession, and use vary by country and even by state. Verify the rules in your jurisdiction.

"Higher doses always produce better results."

Clinical trial data on the GLP-1 RAs consistently show diminishing efficacy gains and increased adverse-event rates as doses go up. The Jastreboff 2023 retatrutide Phase 2 trial reported the strongest weight reduction at the 12 mg dose (−24.2% at 48 weeks) but also the highest GI adverse-event burden in that arm [5]. Dose-response relationships are not linear.

"Peptides are hormones."

Some peptides are hormones (insulin, GLP-1, oxytocin). Most research peptides discussed in this article are not classical hormones — BPC-157 is a gastric-derived tissue repair compound, GHK-Cu is a copper-binding tripeptide. "Peptide" describes structure, not a functional category.

Frequently Asked Questions

Answers describe the published literature and known limitations — not human therapeutic guidance.

Are peptides legal?

It depends on the compound and the jurisdiction. Semaglutide and tirzepatide are FDA-approved prescription medications and require a valid prescription for clinical use. Most other peptides discussed here (BPC-157, TB-500/Tβ4, CJC-1295, Ipamorelin, IGF-1 LR3, GHK-Cu, Epithalon, SNAP-8) are sold as research chemicals; rules governing their sale, possession, and use vary by country and state. Verify the regulations in your specific jurisdiction.

How are research peptides made?

Most synthetic peptides are produced via solid-phase peptide synthesis (SPPS), a method developed by Bruce Merrifield (Nobel Prize in Chemistry, 1984). The chain is built one amino acid at a time on a solid resin support, then cleaved, purified by HPLC, and lyophilized for stability. Quality varies by supplier — independent third-party testing (HPLC purity, mass-spec identity) is the verification standard.

What is the difference between semaglutide, tirzepatide, and retatrutide?

Three successive generations of incretin-based agents. Semaglutide is a single GLP-1 receptor agonist (mean weight reduction −14.9% vs −2.4% placebo at 68 weeks in STEP 1 [3]). Tirzepatide is a dual GIP/GLP-1 agonist (up to −22.5% at 72 weeks in SURMOUNT-1 [4]). Retatrutide adds a glucagon receptor (−24.2% at 48 weeks at 12 mg in the Phase 2 NEJM trial [5]). Each successive class engages additional receptor pathways.

What is the "Wolverine Stack"?

An informal community label for the combination of BPC-157 and TB-500 (Tβ4). The two compounds engage largely non-overlapping mechanisms in animal injury models — BPC-157 in vascular/angiogenic signaling, Tβ4 in actin dynamics and cell migration. Direct head-to-head studies of the combination in humans have not been published.

How are peptides typically stored?

Lyophilized peptides are typically stored frozen for long-term stability. Once reconstituted with bacteriostatic water, they are kept refrigerated rather than frozen — freezing reconstituted solutions can damage peptide structure via ice crystal formation. Specific stability windows vary by compound; follow the supplier's product-specific guidance.

References

Each entry links to PubMed. Animal vs. human evidence is labelled per study so readers can weigh the evidence appropriately. Specific outcome figures cited in the post are from the original published trials in their study populations — not predictions for any individual reader.

  1. [1]Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed PMID: 16352683 Human (healthy adults, PK/PD)
  2. [2]Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed PMID: 9849822 Animal + in vitro
  3. [3]Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. PubMed PMID: 33567185 Human RCT (STEP 1)
  4. [4]Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. PubMed PMID: 35658024 Human RCT (SURMOUNT-1)
  5. [5]Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514–526. PubMed PMID: 37366315 Human RCT (Phase 2)
  6. [8]Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. PubMed PMID: 14554208 Animal (rat) + in vitro
  7. [9]Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. PubMed PMID: 15565145 Animal (mouse cardiac)

Reference numbering aligns with our companion articles on this site so readers can cross-link individual studies. Reference numbers [6] and [7] (used in our stacking guide for the STEP 4 withdrawal trial and SELECT cardiovascular outcome trial) are not directly cited on this page but are available in that article's references.

Ready to Get Started?

Research-grade peptides from our partner research supplier — for laboratory research use only.

≥98% Purity CoA Available US Shipping